Results 101 to 110 of about 81,119 (304)

Exploring Barriers and Facilitators That Influence Uptake of Oral Pre-Exposure Prophylaxis Among Men Who Have Sex With Men in Bulawayo, Zimbabwe: Key Stakeholder’s Perspectives

American Journal of Men's Health
The world has been on the path to ending HIV and AIDS as a global threat by 2030; despite these efforts, the rate of new HIV infections among men who have sex with men remains very high. This study sought to explore the perceptions of key stakeholders on
Perez Livias Moyo, Wilfred Njabulo Nunu
doaj   +1 more source

POPULATION KNOWLEDGE AND PERCEPTIONS ABOUT HIV, SEROPHOBIA, PREP, AND PEP IN FORTALEZA

Brazilian Journal of Infectious Diseases
Introduction/Objective: HIV infection remains a major global public health challenge, requiring integrated strategies for prevention, diagnosis, and treatment.
Vinicius Machado Salles, Mariana Jales Moura, Caroline Casemiro Gomes, Nathanael Willian Florencio de Freitas, Júlia Almeida Saraiva, Antonio Riquelme Martins Negreiros, Anna Paula Nogueira Nascimento, Thammy Lys Câmara Balbino, Manuel Eloy Leitão de Castro Junior, Lucas Passos Portácio Bezerra, Wirna Queiroz Belem Moreira, Lara Gurgel Fernandes Távora   +11 more
doaj   +1 more source

Factors associated with knowledge of pre-exposure prophylaxis in pregnant women in Cape Town, South Africa [PDF]

, 2019
Pregnant and postpartum women in Southern Africa are at increased risk of HIV infection. Pre-exposure prophylaxis in pregnancy and postpartum periods could significantly reduce the risk of HIV acquisition and transmission in pregnancy.
Davey, Dvora L Joseph, Coates, Thomas J, Farley, Elise, Bekker, Linda-Gail, Myer, Landon, Gomba, Yolanda, DiTullio, David J   +6 more
core   +1 more source

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

British Journal of Clinical Pharmacology, EarlyView.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert, Carl M. J. Kirkpatrick, Rory Marriott, Siladitya Ray Chaudhuri, David Polidori, Bart Remmerie, Michelle P. McIntosh   +6 more
wiley   +1 more source

Analysis of sexually transmitted infections in PrEP users: population assessment in Curitiba, Brazil

DST, 2022
Introduction: The pre-exposure prophylaxis (PrEP) is a globally recognized pharmacological approach, consisting of a daily dose of antiretroviral drugs used to reduce the contamination rate by the human immunodeficiency virus (HIV).
Maria Julia de Moraes Campos Roth, Mariana Rothermel Valderrama, Julia Schemberger Acras, Marjorie Goetz Moro, João Victor Borges Lehmkuhl, Daiane Cristina Pazin   +5 more
doaj  

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed   +24 more
wiley   +1 more source

Predictors of linkage to prevention services after HIV post-exposure prophylaxis (PEP): A single-centre retrospective analysis, years 2019-2024

International Journal of Infectious Diseases
Objectives: Post-exposure prophylaxis (PEP) remains underutilised and real-world data on its role within prevention pathways are limited.We aimed to describe PEP use following sexual exposure and to identify predictors of linkage to prevention services ...
Rozenn Esvan, Giulia Micheli, Alessandro Giacinta, Alessandro Caioli, Virginia Barchi, Alessandra Oliva, Riccardo Schiavone, Alice Lener, Elisabetta Gennaro, Sara Passacantilli, Francesco Vairo, Paolo Faccendini, Andrea Antinori, Valentina Mazzotta   +13 more
doaj   +1 more source

Rabies: An overview

International Journal of Advanced Medical and Health Research, 2014
Rabies is a fatal disease caused by rabies virus, a neurotropic virus and a prototype of Lyssavirus of Rhabdoviridae family. It is transmitted to human beings through infected saliva of dogs and cats during bite.
Tarun Kumar Dutta
doaj   +1 more source

Recent advances in pre-exposure prophylaxis for HIV

BMJ, 2017
Although pre-exposure prophylaxis (PrEP)-the use of antiretroviral drugs by non-infected people to prevent the acquisition of HIV-is a promising preventive option, important public health questions remain. Daily oral emtricitabine (FTC)-tenofovir disoproxil fumarate (TDF) is highly efficacious in preventing the acquisition of HIV in people at risk as a
Desai, M, Field, N, Grant, R, McCormack, S   +3 more
openaire   +4 more sources

Use of a Reduced (4-dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies : Recommendations of the Advisory Committee on Immunization Practices [PDF]

"These recommendations of the Advisory Committee on Immunization Practices (ACIP) update the previous recommendations on human rabies prevention (CDC.

core